92 medicines recommended for approval, including 35 with a new active substance.

The European Medicines Agency (EMA) has published an overview of its key recommendations of 2017 regarding the authorisation of new medicines and the safety monitoring of medicines.

Advances in medicines authorisations are essential for public health as they have the potential to improve the treatment of diseases. In 2017, EMA recommended 92 medicines for marketing authorisation. Of these, 35 had a new active substance, which has never been authorised in the European Union (EU) before. Many of these medicines represent a significant improvement in their therapeutic areas; they include medicines for children, for rare diseases and advanced therapies. An overview can be found in the human medicines highlights published today.